- Home
- Publications
- Publication Search
- Publication Details
Title
Is personalized medicine a dream or a reality?
Authors
Keywords
-
Journal
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
Volume 52, Issue 1, Pages 1-11
Publisher
Informa UK Limited
Online
2014-09-02
DOI
10.3109/10408363.2014.950407
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 23andMe and the FDA
- (2014) George J. Annas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Narrative Review: Statin-Related Myopathy
- (2013) Tisha R. Joy ANNALS OF INTERNAL MEDICINE
- Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects
- (2013) Liu Mao et al. Archives of Cardiovascular Diseases
- CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy
- (2013) Wendy A. Teft et al. BREAST CANCER RESEARCH AND TREATMENT
- Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban
- (2013) Inna Y. Gong et al. CANADIAN JOURNAL OF CARDIOLOGY
- Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care
- (2013) Marianne K. DeGorter et al. Circulation-Cardiovascular Genetics
- Prediction of Warfarin Maintenance Dose in Han Chinese Patients Using a Mechanistic Model Based on Genetic and Non-Genetic Factors
- (2013) Yuan Lu et al. CLINICAL PHARMACOKINETICS
- CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
- (2013) M A Province et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
- (2013) S A Scott et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Genetics and Personalized Medicine—a Role in Statin Therapy?
- (2013) Jaideep Patel et al. Current Atherosclerosis Reports
- Metabolic differences of current thienopyridine antiplatelet agents
- (2013) Jawed Fareed et al. Expert Opinion on Drug Metabolism & Toxicology
- Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies
- (2013) Kazuma Kiyotani et al. JOURNAL OF HUMAN GENETICS
- Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
- (2013) Minoli A Perera et al. LANCET
- A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
- (2013) Lara M. Mangravite et al. NATURE
- A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
- (2013) Stephen E. Kimmel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Genotype-Guided Dosing of Warfarin
- (2013) Munir Pirmohamed et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients
- (2013) Hon-Kit Lee et al. PHARMACOGENOMICS
- Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans
- (2013) W Hernandez et al. PHARMACOGENOMICS JOURNAL
- The pharmacogenomics of statins
- (2013) Ingrid C. Gelissen et al. PHARMACOLOGICAL RESEARCH
- Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1
- (2013) Anne T Nies et al. Genome Medicine
- Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel
- (2012) Jae-Sik Jang et al. AMERICAN JOURNAL OF CARDIOLOGY
- Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes
- (2012) Rui Chen et al. CELL
- Evidence-Based Management of Anticoagulant Therapy
- (2012) Anne Holbrook et al. CHEST
- Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction
- (2012) Daniel I. Chasman et al. Circulation-Cardiovascular Genetics
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Clopidogrel: A Case for Indication-Specific Pharmacogenetics
- (2012) J A Johnson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response
- (2012) Inna Y. Gong et al. Drug Metabolism and Pharmacokinetics
- Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response
- (2012) Inna Y. Gong et al. EUROPEAN HEART JOURNAL
- Current Understanding of Drug Disposition in Kidney Disease
- (2012) Judith Naud et al. JOURNAL OF CLINICAL PHARMACOLOGY
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- PharmGKB summary
- (2012) Jatinder Lamba et al. Pharmacogenetics and Genomics
- Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy
- (2011) I. Y. Gong et al. BLOOD
- Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
- (2011) T E Mürdter et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing
- (2011) J A Johnson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters
- (2011) Kazuma Kiyotani et al. Drug Metabolism and Pharmacokinetics
- P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration
- (2011) D. Iusuf et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Clopidogrel–Drug Interactions
- (2011) Eric R. Bates et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation
- (2011) Inna Y. Gong et al. PLoS One
- Warfarin Dosing in Patients With Impaired Kidney Function
- (2010) Nita A. Limdi et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction
- (2010) Kristian M. Bailey et al. Circulation-Cardiovascular Genetics
- ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin
- (2010) B Tomlinson et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)
- (2010) W. A. Teft et al. DRUG METABOLISM AND DISPOSITION
- Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
- (2010) Vincent O. Dezentjé et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study
- (2010) Rolf P Kreutz et al. PHARMACOTHERAPY
- Impact of OATP transporters on pharmacokinetics
- (2009) A Kalliokoski et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome
- (2009) Jeremy A. Rassen et al. CIRCULATION
- ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
- (2009) J E Keskitalo et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
- (2009) Alan R. Shuldiner JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin
- (2009) Jenni E Keskitalo et al. PHARMACOGENOMICS
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
- (2008) BF Gage et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance
- (2008) KA Kim et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin
- (2008) Martine Gilard et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects
- (2008) K. UMEMURA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Genetic Determinants of Response to Warfarin during Initial Anticoagulation
- (2008) Ute I. Schwarz et al. NEW ENGLAND JOURNAL OF MEDICINE
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More